Dana P. Goldman

Papers

Total Citations

H-Index

About

Dana P. Goldman is a leading health economist whose research lies at the intersection of healthcare innovation, pharmaceutical policy, and medical technology assessment. Her work has profoundly shaped our understanding of how new treatments and technologies affect patient outcomes, healthcare costs, and access to care. In a landmark 2015 study (18 citations), Goldman demonstrated that robot-assisted surgery for kidney cancer significantly increased access to a life-saving procedure, reducing both mortality and renal failure—a critical finding for hospitals weighing the substantial investment in robotic systems against long-term patient benefits. More recently, her forward-looking 2021 survey (30 citations) brought together leaders from pharmacy and non-pharmacy industries to map the evolving needs of pharmacy education through 2030, ensuring the profession remains responsive to rapid technological and scientific change. Goldman’s work consistently bridges clinical evidence and health policy, providing decision-makers with the data needed to allocate resources wisely. Her research has been instrumental in evaluating the real-world impact of medical innovations, making her a vital voice in the ongoing debate over value-based care and the future of pharmaceutical sciences.